In This Article
The short answer: hs-CRP (high-sensitivity C-reactive protein) is a blood test that measures low-grade, systemic inflammation. The liver produces it in response to a signal from the immune system, and a sustained elevation is one of several markers doctors use, alongside LDL cholesterol, to estimate long-term cardiovascular risk. It is not a diagnostic test on its own: a single high number is often explained by a cold, an injury, obesity, or another non-cardiac source of inflammation, which is why guidelines call for repeat testing and context before treating a result as meaningful.
- What hs-CRP Measures
- How It Assesses Risk
- The Research Behind It
- The Common Misconception
- What Drives an Elevated Number
- What To Actually Do
- FAQ
- Key Takeaways
- References
Read key takeaways →
What hs-CRP actually measures
C-reactive protein is an acute-phase protein made almost exclusively by liver cells, not by the heart, blood vessels, or immune cells directly. Cem Gabay and Irving Kushner's widely cited 1999 review in the New England Journal of Medicine describes how the liver ramps up production in response to interleukin-6 (IL-6), a signaling molecule released by immune cells whenever the body detects tissue damage, infection, or another inflammatory trigger. CRP itself does not cause inflammation. It is a downstream messenger, a blood marker that rises because something upstream told the liver to make more of it.
The "hs" in hs-CRP stands for high-sensitivity, and it refers to the assay, not a different molecule. A standard CRP test, the kind ordered to check for an active infection, is built to measure the large swings that come with acute illness and is not precise at the low end of the scale. A high-sensitivity assay can reliably detect CRP within the normal range, which is what makes it useful for comparing cardiovascular risk between people who all look clinically well.
How a CRP Rise Actually Unfolds
A stimulus, an infection, an injury, or another inflammatory trigger, prompts immune cells to release IL-6.
IL-6 reaches the liver and switches on rapid CRP production in hepatocytes.
Mark Pepys and Gideon Hirschfield's 2003 kinetics review in the Journal of Clinical Investigation found plasma CRP rising above 5 mg/L by around 6 hours after a single stimulus, then peaking around 48 hours.
CRP's plasma half-life holds steady at about 19 hours in both health and disease, so once the stimulus fades, the level falls fairly quickly because production, not clearance, is what drives the number.
How hs-CRP is used to assess cardiovascular risk
The framework most labs and clinicians still reference comes from a 2003 joint statement from the Centers for Disease Control and Prevention and the American Heart Association, led by Thomas Pearson and published in Circulation. It sorted hs-CRP into three bands for estimating added cardiovascular risk on top of standard tools like the Framingham risk score.
Below 1 mg/L
Lower added risk
The CDC/AHA statement's lower risk category for long-term cardiovascular risk assessment.
1 to 3 mg/L
Average added risk
The middle category, used alongside lipid values rather than as a standalone verdict.
Above 3 mg/L
Higher added risk
The higher risk category, worth discussing with a clinician alongside a full lipid panel.
These bands were built for cardiovascular risk stratification specifically, not as a general reading of inflammation. The same statement recommends measuring hs-CRP twice, ideally about two weeks apart while a person is otherwise feeling well, and averaging the two results rather than acting on a single draw. It also draws a hard line at 10 mg/L: values that high point toward an acute inflammatory process, an infection, a recent injury, a flare of an autoimmune condition, rather than baseline cardiovascular risk, and the guideline calls for finding the cause and retesting once it resolves instead of plugging that number into a risk score.
Because hs-CRP measures inflammation broadly rather than anything specific to the arteries, it is meant to sit alongside other data, not replace it. Pairing it with a full lipid panel gives a fuller picture than either number alone.
The research behind hs-CRP and heart disease
The case for hs-CRP did not come from one study. Paul Ridker and colleagues first linked it to cardiovascular risk in a 1997 New England Journal of Medicine analysis of the Physicians' Health Study, where men in the highest baseline CRP quartile had roughly three times the risk of a future heart attack and about twice the risk of ischemic stroke compared with men in the lowest quartile, years before any event occurred.
Ridker's group extended this into women in a 2000 New England Journal of Medicine analysis of the Women's Health Study, and followed it in 2002 with a head-to-head comparison of hs-CRP and LDL cholesterol in nearly 28,000 women. hs-CRP and LDL were only weakly correlated with each other, yet each independently tracked with future cardiovascular events, which is the basis for using both rather than treating one as a substitute for the other. A 2024 New England Journal of Medicine follow-up of that same cohort, tracking outcomes across 30 years, found that hs-CRP, LDL cholesterol, and lipoprotein(a) each added independent, additive information about long-term cardiovascular risk.
JUPITER trial. Ridker and colleagues randomized apparently healthy people with normal LDL cholesterol but hs-CRP at or above 2 mg/L to rosuvastatin or placebo. The statin group had significantly fewer major cardiovascular events and lower all-cause mortality, evidence that an elevated hs-CRP can flag risk even when cholesterol looks fine.
CANTOS trial. In people with a prior heart attack and hs-CRP at or above 2 mg/L, an antibody that blocks interleukin-1β, canakinumab, lowered the rate of recurrent cardiovascular events compared with placebo without changing LDL cholesterol at all. It was the first trial to show that targeting inflammation directly, independent of lipid lowering, can reduce cardiovascular events.
Together, these trials are why hs-CRP is treated as more than a passive bystander marker: it identifies a group of people whose risk is not fully explained by cholesterol, and in CANTOS, deliberately lowering inflammation changed outcomes.
The common misconception
A single elevated hs-CRP result is not a heart disease diagnosis, and a normal one does not clear a person of cardiovascular risk. hs-CRP measures inflammation in general. A cold, a sprained ankle, a poor night of sleep, or a dental cleaning can all push it up temporarily, with nothing to do with the arteries.
The mistake runs in both directions. Treating any elevated number as alarming ignores how common non-cardiac causes are, and how explicitly the guidelines call for repeat testing before drawing conclusions. Treating hs-CRP as irrelevant swings too far the other way and ignores three decades of research tying a persistently elevated, repeat-confirmed level to added cardiovascular risk that is not visible on a lipid panel alone. The number is only informative once acute, non-cardiac explanations have been reasonably ruled out and the result has been confirmed on a second draw.
What actually drives an elevated number
Because hs-CRP responds to IL-6 from almost any source, plenty of things unrelated to heart disease can raise it. None of these need to be present for hs-CRP to matter for cardiovascular risk, but they are worth ruling out before treating a high number as a cardiac signal, the same way chronic stress and poor sleep quietly shift other inflammatory markers.
Excess body fat, especially visceral fat
Adipose tissue itself secretes IL-6, the same cytokine that drives hepatic CRP production, which is part of why obesity is consistently linked to higher baseline hs-CRP.
Smoking
A well established driver of systemic low-grade inflammation, independent of its other cardiovascular effects.
Acute infection or recent injury
Exactly the scenario the CDC/AHA guideline flags with its above-10 mg/L cutoff. Retesting after recovery is the recommended fix, not interpreting the number as-is.
Autoimmune and chronic inflammatory conditions
Rheumatoid arthritis, inflammatory bowel disease, and similar conditions can keep hs-CRP elevated independent of cardiovascular status.
Poor sleep and chronic stress
Both are associated with higher circulating inflammatory markers, another reason a single bad week is not the moment to draw the test.
What to actually do with an hs-CRP number
Test twice, not once. The CDC/AHA guideline calls for two measurements roughly two weeks apart while feeling well, and averaging them, rather than acting on a single draw.
Rule out an obvious non-cardiac cause first. A recent illness, injury, dental work, or flare of a known inflammatory condition should push the retest later rather than treating that value as baseline.
Read it next to your lipid panel, not instead of it. hs-CRP is designed to add information to LDL cholesterol and other lipid values, the way it did in Ridker's research, not to replace them.
Work the modifiable drivers. Reducing excess body fat, stopping smoking, and improving sleep are reasonable first steps for a persistently elevated, repeat-confirmed result, alongside the same habits that support a healthier full blood count and metabolic profile.
Bring a persistently high, confirmed result to a clinician. Deciding whether it changes a statin recommendation, warrants further workup, or is simply worth monitoring is a conversation for a doctor with your full history, not a number to self-diagnose from.
Frequently asked questions
Is hs-CRP the same test my doctor orders when I might have an infection?
Can lifestyle changes actually lower hs-CRP?
Does a high hs-CRP mean I have heart disease?
Do I need to fast before an hs-CRP test?
What does it mean if my hs-CRP comes back above 10 mg/L?
Should everyone get hs-CRP tested?
What to Remember
- →hs-CRP is a high-sensitivity assay for C-reactive protein, an acute-phase protein the liver produces in response to interleukin-6. It reflects systemic inflammation broadly, not damage to the heart specifically.
- →The 2003 CDC/AHA statement (Pearson et al.) categorizes cardiovascular risk as lower below 1 mg/L, average from 1 to 3 mg/L, and higher above 3 mg/L, based on two measurements averaged roughly two weeks apart, not a single draw.
- →Values above 10 mg/L usually reflect an acute cause such as infection or injury and should be investigated and retested rather than used for cardiovascular risk assessment.
- →Landmark studies from Paul Ridker and colleagues, including the 1997 and 2000 Physicians’ Health Study and Women’s Health Study analyses and a 2024 30-year follow-up, found hs-CRP adds independent, additive information to LDL cholesterol and lipoprotein(a) rather than duplicating it.
- →The JUPITER (2008) and CANTOS (2017) trials showed that treating elevated hs-CRP, whether with a statin or a targeted anti-inflammatory antibody, reduced cardiovascular events, which is why hs-CRP is treated as more than a passive marker.
Related on Protocol
How to Interpret Your Lipid Panel: LDL Particles, ApoB, and What Actually Matters
The cholesterol side of cardiovascular risk that hs-CRP is meant to complement, not replace.
How to Read a CBC Without Overreacting to Noise
The same repeat-before-you-react approach applied to a different panel of commonly misread blood values.
The Lab Work and Biomarkers Protocol
A framework for deciding which labs are worth tracking over time and which ones need clinical context before acting.
Track inflammation alongside the rest of your health data
Protocol keeps your lab markers, wearable trends, and recovery data in one place, so a single number is never read in isolation.
Get started freeReferences
Key Researchers
- Paul Ridker (Brigham and Women’s Hospital, Harvard Medical School) Led the Physicians’ Health Study, Women’s Health Study, JUPITER, and CANTOS analyses that established hs-CRP as an independent cardiovascular risk marker and inflammation as a treatable target.
- Mark Pepys and Gideon Hirschfield (University College London) Authored the widely cited 2003 review establishing the kinetics and biology of CRP production and clearance.
- Cem Gabay and Irving Kushner Authored the foundational 1999 review of acute-phase proteins and the cytokine signaling, including IL-6, that drives hepatic CRP production.
Key Studies and Guidelines
- Pearson et al. (2003) Circulation. CDC/AHA joint statement establishing the below-1, 1-to-3, and above-3 mg/L risk categories and the two-measurement testing protocol still referenced today.
- Gabay and Kushner (1999) New England Journal of Medicine. Review of acute-phase proteins and the IL-6-driven hepatic response to inflammation.
- Pepys and Hirschfield (2003) Journal of Clinical Investigation. Critical review of CRP biology, including its roughly 19-hour plasma half-life and rise-and-peak kinetics after a stimulus.
- Ridker et al. (1997) New England Journal of Medicine. Physicians’ Health Study analysis linking higher baseline CRP to future heart attack and stroke risk in healthy men.
- Ridker et al. (2000) New England Journal of Medicine. Women’s Health Study analysis extending the CRP-cardiovascular risk association to women.
- Ridker et al. (2002) New England Journal of Medicine. Head-to-head comparison finding hs-CRP and LDL cholesterol were only weakly correlated yet each independently predicted cardiovascular events.
- Ridker et al. (2008) New England Journal of Medicine. The JUPITER trial, showing rosuvastatin reduced cardiovascular events in people with normal LDL but elevated hs-CRP.
- Ridker et al. (2017) New England Journal of Medicine. The CANTOS trial, showing an anti-IL-1β antibody reduced recurrent cardiovascular events independent of cholesterol lowering.
- Ridker et al. (2024) New England Journal of Medicine. A 30-year follow-up of the Women’s Health Study finding hs-CRP, LDL cholesterol, and lipoprotein(a) each contribute additive long-term cardiovascular risk information.
Apps and Tools
- Protocol Tracks lab markers like hs-CRP alongside lipid panels, wearable data, and recovery trends so single values are read in context.
